Literature DB >> 15849220

Jaw avascular bone necrosis associated with long-term use of biphosphonates.

G Sanna, M G Zampino, G Pelosi, F Nolè, A Goldhirsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15849220     DOI： 10.1093/annonc/mdi206

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

Review 1.  [Bisphosphonate-associated osteonecrosis of the jaw].

Authors:  M H Abu-Id; Y Açil; J Gottschalk; T Kreusch
Journal:  Mund Kiefer Gesichtschir       Date:  2006-03

2.  Bisphosphonate-related osteonecrosis of the jaw: clinical correlations with computerized tomography presentation.

Authors:  Sharon Elad; Moshe J Gomori; Noa Ben-Ami; Silvina Friedlander-Barenboim; Eran Regev; Towy S Lazarovici; Noam Yarom
Journal:  Clin Oral Investig       Date:  2009-07-15       Impact factor: 3.573

3.  Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.

Authors:  Ana O Hoff; Béla B Toth; Kadri Altundag; Marcella M Johnson; Carla L Warneke; Mimi Hu; Ajay Nooka; Gilbert Sayegh; Valentina Guarneri; Kimberly Desrouleaux; Jeffrey Cui; Andrea Adamus; Robert F Gagel; Gabriel N Hortobagyi
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

4.  Therapeutic and Preventive Effects of Osteoclastogenesis Inhibitory Factor on Osteolysis, Proliferation of Mammary Tumor Cell and Induction of Cancer Stem Cells in the Bone Microenvironment.

Authors:  Mitsuru Futakuchi; Takao Nitanda; Saeko Ando; Harutoshi Matsumoto; Eri Yoshimoto; Katsumi Fukamachi; Masumi Suzui
Journal:  Int J Mol Sci       Date:  2018-03-16       Impact factor: 5.923

5.  Blue Mussel-Derived Peptides PIISVYWK and FSVVPSPK Trigger Wnt/β-Catenin Signaling-Mediated Osteogenesis in Human Bone Marrow Mesenchymal Stem Cells.

Authors:  Yunok Oh; Chang-Bum Ahn; Jae-Young Je
Journal:  Mar Drugs       Date:  2020-10-09       Impact factor: 5.118
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.